GlassScriptPhysician profile
Lily Zhang
NPI 1942453444
$16,152.93
in general payments reported to CMS, 2019-2025
23 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $238 · 2021: $333 · 2022: $3,478 · 2023: $9,362 · 2024: $1,803 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,300 · Food and Beverage: $1,364 · Travel and Lodging: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,300.00 |
| Food and Beverage | $1,364.20 |
| Travel and Lodging | $1,046.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $11,850.00 | 2022-2023 | |
| Abbott Laboratories | $2,137.59 | 2022-2025 | Mitraclip |
| Boston Scientific Corporation | $472.54 | 2019-2022 | |
| Edwards Lifesciences Corporation | $338.27 | 2021-2025 | Evoque, Sapien 3 Ultra Resilia |
| Sun Pharmaceutical Industries INC. | $235.26 | 2024-2025 | |
| Biotronik INC. | $186.76 | 2021-2022 | |
| Teleflex LLC | $169.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $114.06 | 2019 | |
| Medtronic, INC. | $109.75 | 2023-2025 | Corevalve Evolut R |
| Ge Healthcare | $100.34 | 2019-2020 | |
| Philips North America LLC | $72.45 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $61.85 | 2019-2020 | |
| Chiesi USA, INC. | $61.51 | 2021-2022 | |
| Terumo Medical Corporation | $47.47 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.70 | 2021-2025 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $34.55 | 2025 | |
| W. L. Gore & Associates, INC. | $24.47 | 2021 | |
| Heartflow, INC. | $22.50 | 2024 | |
| Dompe US, INC. | $20.79 | 2024 | Oxervate |
| Actelion Pharmaceuticals US, INC. | $20.78 | 2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $20.36 | 2019 | |
| Amgen INC. | $15.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.